COMPANY PROFILE

Amytrx Therapeutics

Advancing a new class of peptide therapies to empower the body's natural intracellular regulatory mechanisms to control inflammation and metabolic disease

Nashville, United StatesFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Amytrx Therapeutics

Amytrx Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel peptide therapies for the treatment of inflammatory and metabolic diseases. The company operates in the biopharmaceutical market, serving clients such as pharmaceutical and biotechnology companies, as well as clinical and research organizations. Amytrx's business model revolves around leveraging its exclusive rights to an extensive portfolio of patents in the US and EU, obtained through a partnership with Vanderbilt University. The company aims to advance new or complementary therapies for chronic diseases characterized by excessive inflammation or metabolic imbalances. Amytrx generates revenue through collaborative opportunities with pharmaceutical and biotechnology partners, as well as through the development and commercialization of its proprietary therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Nashville, United States
Employees: 2
Open positions: None listed
Dealroom signal: 58.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b, b2c
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Feb 2024	$3M	$90M	Undisclosed	—
DEBT✓Debt	Feb 2024	$6M	—	Undisclosed	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Amytrx Therapeutics website traffic

Latest recorded traffic for Amytrx Therapeutics is 3.3K monthly website visits, up 120% over the last three months. Amytrx Therapeutics's team declined 33.3% over the past year.

Latest monthly visits3.3K 3-month web change+120% 1-year team growth-33.3%

Monthly website visitsAug 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
EPEpiPawsOffering DNA testing for pets in order to estimate their age	Fort Lauderdale, United States	Operational	12	$25K	—
TPTME PharmaDeveloping novel therapies for treatment of the most aggressive cancers by acting on the tumor microenvironment (TME)	Berlin, Germany	Operational
ELElephasA live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development	Garrett Park, United States	Operational
HAHaiiDeveloping innovative digital therapeutics in the prevention and management of mental health and disease such as dementia, depression, and anxiety disorders	Seoul, South Korea	Operational
DIDIADEMImproves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome	London, United Kingdom	Operational
NANanopathA molecular diagnostics company disrupting traditional testing methodologies	Cambridge, United States	Operational
REResBioticMobilizing an ecosystem of support for the world inside the lungs	Birmingham, United States	Operational
HCHealthTech ConnexHealthTech Connex Inc. focuses on technology-based innovations for rapid impact in health improvements and outcomes	Surrey, Canada	Operational